(Q41592435)

4 October 2017

0 references

Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma (English)

1 reference

4 October 2017

1 reference

2

Lorenzo Galluzzi

1 reference

4 October 2017

1

Guido Kroemer

0 references

language of work or name

1 reference

2 March 2015

1 reference

4 October 2017

1 reference

4 October 2017

4

1 reference

4 October 2017

6

1 reference

4 October 2017

e1008853

1 reference

Classification of current anticancer immunotherapies

4 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Nivolumab in previously untreated melanoma without BRAF mutation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial Watch: Adoptive cell transfer for anticancer immunotherapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Impact of myeloid cells on the efficacy of anticancer chemotherapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial Watch: Anticancer radioimmunotherapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Immunogenic cell death in cancer therapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

State of the art in the treatment of Hodgkin lymphoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

The secret ally: immunostimulation by anticancer drugs

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Consensus guidelines for the detection of immunogenic cell death

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial Watch: Radioimmunotherapy for oncological indications

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485757

Trial watch: Monoclonal antibodies in cancer therapy

19 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F2162402X.2015.1008853

THE ORIGIN OF HODGKIN AND REED/STERNBERG CELLS IN HODGKIN'S DISEASE

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F2162402X.2015.1008853

10.1080/2162402X.2015.1008853

21 January 2018

Identifiers

DOI

1 reference

release_jz4q3jxx3rbo7cmd4xdfrxitb4

4 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jz4q3jxx3rbo7cmd4xdfrxitb4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

4485757

1 reference

PMC publication ID

4485757

4 October 2017

PubMed publication ID

26155425

1 reference

PMC publication ID

4485757